- Investigator
- Roberto J Firpi-Morell
Clinical trials
-
AK-US-001-0107 Efruxifermin Non-Invasive dx NASH/NAFL -
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE) The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with…
- Investigator
- Padraic O'Malley
- Ages
- 18 Years - N/A
- Sexes
- All
-
Addition of Pembrolizumab to Usual Intravesical Gemcitabine for Treatment of BCG-Unresponsive NMIBC This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as…
- Investigator
- Paul L Crispen
- Ages
- 18 Years - N/A
- Sexes
- All
-
BL infusion trial The study plans to randomize a total of 240 patients infected with Gram-negative bacterial pneumonia to receive beta-lactam (meropenem, cefepime, or piperacillin/tazobactam) continuous or intermittent infusion and collect baseline and regular…
- Ages
- 18 Years - 100 Years
- Sexes
- All
-
u-STOP LVAD Bleed This is a Phase I, single ascending dose, first in human, open-label, non-controlled, dose-escalation trial that will investigate intravenous infusions of Umbilical cord lining stem cells (UCLSCs) in Left Ventricular Assist Device (LVAD)…
- Investigator
- Mustafa M Ahmed
- Ages
- 18 Years - 80 Years
- Sexes
- All